Shots: Oxford Biomedica and VMIC entered into a five-year agreement for the manufacturing of adenovirus vector-based COVID-19 vaccine, AZD1222 for scaling up the production of the vaccine from the summer of 2020 to meet the demand in UK and EU VMIC will provide manufacturing equipment whereas Oxford Biomedica will provide training and technical assistance to […]Read More
